Brokers Issue Forecasts for AVXL Q1 Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Anavex Life Sciences in a research note issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will post earnings per share of ($0.18) for the quarter. HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03.

Separately, D. Boral Capital reissued a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, February 12th.

Anavex Life Sciences Trading Up 0.1 %

NASDAQ:AVXL opened at $8.71 on Wednesday. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $14.44. The company has a market cap of $740.45 million, a P/E ratio of -15.83 and a beta of 0.69. The company’s 50-day moving average price is $9.97 and its 200-day moving average price is $7.76.

Institutional Investors Weigh In On Anavex Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in shares of Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 1,708 shares during the period. Berkshire Money Management Inc. acquired a new position in Anavex Life Sciences in the fourth quarter valued at approximately $107,000. Prudential Financial Inc. purchased a new position in Anavex Life Sciences in the fourth quarter worth approximately $109,000. Fiduciary Alliance LLC acquired a new stake in Anavex Life Sciences during the fourth quarter worth $119,000. Finally, D.A. Davidson & CO. purchased a new stake in Anavex Life Sciences in the fourth quarter valued at $122,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.